Plain-English translation of NCT07032792 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
After heart surgery, some patients experience excessive bleeding that doctors need to treat quickly. This trial is testing whether , a medication that helps blood clot, works better than the standard treatment (fresh frozen plasma) for stopping this kind of bleeding. The goal is to find out which treatment is most effective at controlling bleeding in heart surgery patients.
Bleeding after heart surgery is common and can lead to serious problems for patients. Doctors need better ways to stop this bleeding quickly and safely. This trial exists to see whether this medication could be a more effective first-line option than what is currently used.
You likely qualify if…
You likely don't qualify if…
If you qualify, you would be randomly assigned to receive either the new medication () or the standard treatment (fresh frozen plasma) if you develop bleeding after your heart surgery. The study team would monitor how well each treatment controls your bleeding and track your recovery. Your participation would include standard follow-up care related to your surgery.
AI-generated summary from trial data · Jun 2, 2026 · Not medical advice
United States
Testing effectiveness
Sponsor
Northwell Health
Enrollment target
~140 participants
Started
November 2025
Primary completion
November 2028
Age range
18 Years and older
Last updated on clinicaltrials.gov in March 2026.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Kristine McGowan
Northwell Health
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.